Table 2.
Summary estimates of sensitivity, specificity, +LR, −LR, DOR, and SROC curve (AUC) of MPV for the identification of PE in different subgroups.
| Variables | No. | Sensitivity (95% CI) | Specificity (95% CI) | +LR (95% CI) | −LR (95% CI) | DOR (95% CI) | SROC curve AUC ± SE | |
|---|---|---|---|---|---|---|---|---|
| Total | 22 | 0.676 (0.658–0.694) | 0.710 (0.703–0.717) | 2.576 (2.006–3.308) | 0.381 (0.277–0.523) | 7.012 (4.226–11.636) | 0.7889 ± 0.0300 | |
| Gestational week at sampling | Before 20 weeks | 9 | 0.771 (0.744–0.796) | 0.651 (0.643–0.660) | 1.939 (1.332–2.823) | 0.393 (0.251–0.613) | 5.165 (2.582–10.332) | 0.7467 ± 0.0490 |
| After 20 weeks | 13 | 0.616 (0.591–0.640) | 0.835 (0.825–0.845) | 3.187 (2.075–4.897) | 0.374 (0.247–0.568) | 8.661 (4.156–18.048) | 0.8387 ± 0.0378 | |
| Sample size | <350 | 16 | 0.656 (0.632–0.680) | 0.721 (0.701–0.740) | 2.469 (1.853–3.290) | 0.432 (0.321–0.581) | 5.996 (3.742–9.608) | 0.7700 ± 0.0326 |
| ≥350 | 6 | 0.702 (0.675–0.729) | 0.709 (0.701–0.716) | 2.836 (1.788–4.498) | 0.277 (0.100–0.766) | 10.268 (3.007–35.064) | 0.8169 ± 0.0665 | |
| Cut-off | <9 | 7 | 0.734 (0.700–0.766) | 0.663 (0.647–0.680) | 1.756 (1.151–2.678) | 0.470 (0.353–0.624) | 4.021 (2.034–7.951) | 0.7363 ± 0.0543 |
| ≥9 | 15 | 0.654 (0.632–0.676) | 0.721 (0.713–0.728) | 3.137 (2.354–4.181) | 0.352 (0.227–0.547) | 9.129 (4.614–18.059) | 0.8421 ± 0.0294 | |
| Country | China | 7 | 0.631 (0.595–0.666) | 0.687 (0.652–0.721) | 2.246 (1.367–3.690) | 0.412 (0.232–0.731) | 5.819 (2.729–12.405) | 0.7657 ± 0.0525 |
| Other countries | 15 | 0.693 (0.672–0.714) | 0.711 (0.704–0.718) | 2.735 (2.035–3.677) | 0.366 (0.244–0.551) | 7.658 (3.994–14.682) | 0.7995 ± 0.0380 | |
| Reference standard | ACOG | 12 | 0.659 (0.635–0.682) | 0.723 (0.712–0.735) | 2.052 (1.329–3.168) | 0.434 (0.308–0.611) | 4.843 (2.645–8.867) | 0.7436 ± 0.0487 |
| Obstetrics and gynecology | 3 | 0.405 (0.353–0.458) | 0.834 (0.778–0.881) | 2.446 (1.163–5.141) | 0.652 (0.401–1.062) | 3.768 (1.096–12.953) | 0.8642 ± 0.1015 | |
| Guideline | 1 | 0.900(–) | 0.390(–) | — | — | — | 0.647 | |
| ISSHP | 1 | 0.78(–) | 0.86(–) | — | — | — | 0.748 | |
| Clinical diagnostic criteria | 5 | 0.863 (0.831–0.892) | 0.684 (0.674–0.693) | 4.572 (2.401–8.705) | 0.233 (0.103–0.528) | 20.367 (9.970–41.608) | 0.8927 ± 0.0198 | |
| Study design | Prospective | 5 | 0.835 (0.797–0.868) | 0.673 (0.664–0.682) | 2.703 (1.806–4.047) | 0.351 (0.146–0.848) | 8.062 (2.477–26.245) | 0.8053 ± 0.0589 |
| Retrospective | 11 | 0.591 (0.565–0.616) | 0.609 (0.591–0.627) | 1.659 (1.405–1.959) | 0.550 (0.437–0.693) | 3.279 (2.468–4.356) | 0.6889 ± 0.0228 | |
| NR | 6 | 0.755 (0.722–0.787) | 0.864 (0.854–0.874) | 5.189 (3.710–7.260) | 0.219(0.081–0.593) | 23.481(8.211–67.146) | 0.9293 ± 0.0073 | |